ESR1: Ben He


ESR2: Vasileios Fougiaxis


ESR3: Evgenia-Galateia Georgaki


ESR4: Martha - Spyridoula Nikopaschou


ESR5: Shami Álvarez Mourid

  • Effect of Modulation of ERAP1 activity in antigen processing and presentation
  • University of Southampton - "Cancer Sciences Unit" Lab

ESR6: Dario Vinicio Guglietta

  • Effect of ERAP1 modulation on induction of protective anti-tumour immunity
  • University of Southampton - "Cancer Sciences Unit" Lab

ESR7: Alice Senni


ESR8: Nadia Keelan


ESR9: Paula Gragera Alvarez

  • ERAP modulation as an innovative strategy for cancer treatment
  • Ospedale Pediatrico Bambino Gesù. Roma, IT. - "Onco-haematology" Lab

ESR10: Kamila Król

  • In vivo anti-tumour safety and efficacy of NK cell-based immunotherapeutic approach in preclinical models
  • Ospedale Pediatrico Bambino Gesù. Roma, IT. - "Onco-haematology" Lab

ESR11: Sandra Llamas Rizo

  • Design, synthesis and evaluation of phosphinic transition-state analogues of ERAP/IRAP
  • National and Kapodistrian University of Athens, GR - "Organic Chemistry" Lab

ESR12: Aroosha Raja

  • Molecular ecosystem of ERAP four distinct immune cell subsets from patients with ERAP-linked diseases
  • University Medical Center Utrecht, NL - "BoerKuiper group"

ESR13: Adele Ponzoni

  • Biomarkers discovery, compounds distribution, efficacy and toxicity analysis by Mass Spectrometry Imaging
  • Imabiotech

ESR14: Filipa da Silva de Vasconcelos

  • Development of drug delivery systems for ERAP/IRAP modulators
  • Inocure

ESR15: Nikoletta Maria Koutroumpa